Why Everyone Has A Stake In The Chimerix Drug Offered To Josh Hardy (CMX001; Brincidofovir)

March 13, 2014 2:26 AM

28 0

A small biotechnology company agreed yesterday to provide their experimental, antiviral drug for the treatment of a seven-year-old Virginia boy, Joshua Hardy, who is currently suffering from a life-threatening adenovirus infection acquired during his cancer treatment at St. Jude Children’s Hospital.

The company, North Carolina-based Chimerix, had originally declined a request by the Hardy family to provide the drug, known as CMX001 or brincidofovir, under the “compassionate use” provision for unapproved drugs.

Read more

To category page